	US 12,247,232 B2
	Methods and compositions for inhibiting ADAM 9 biological activities
Marcia L. Moss, Apex, NC (US); Robert Rasmussen, Lansing, NY (US); and Chris Prince, Ithaca, NY (US)
Assigned to VERRA THERAPEUTICS, INC., Lansing, NY (US)
Filed by VERRA THERAPEUTICS, INC., Lansing, NY (US)
Filed on Jan. 31, 2019, as Appl. No. 16/263,671.
Claims priority of provisional application 62/624,491, filed on Jan. 31, 2018.
Prior Publication US 2019/0382745 A1, Dec. 19, 2019
Int. Cl. C12N 9/64 (2006.01); A61K 38/48 (2006.01); A61K 47/60 (2017.01); A61P 19/04 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01); A61K 38/55 (2006.01)

CPC C12N 9/6489 (2013.01) [A61K 38/4886 (2013.01); A61K 47/60 (2017.08); A61P 19/04 (2018.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01); A61K 38/55 (2013.01); C07K 2319/00 (2013.01)]

21 Claims

1. A peptide comprising SEQ ID NO: 3, wherein relative to the amino acid sequence set forth in SEQ ID NO: 2, the peptide includes one or more amino acid substitutions and/or chemical modifications at amino acid position(s) 85, 104, and 146, wherein the substitution(s) are selected from substitution of the cysteine with serine, alanine, or glycine.